Skip to main content

Table 2 Engraftment and GVHD

From: The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party

 

HLA 10/10

HLA 9/10

HLA 8/10

p value

Total number of patients

2567

723

108

 

Engraftment, n (%)

2458 (97.3 %)

678 (96.3 %)

101 (97.12 %)

0.313

 No engraftment, n (%)

67 (2.7 %)

26 (3.7 %)

3 (2.9 %)

 

 Missing, n

42

19

5

 

Median time ANC >0.5 G/L (days, range)

16 (0–103)

16 (1–165)

15.5 (1–33)

0.538

Acute GVHD,

    

 Grade 0–I, n (%)

1826 (74.4 %)

469 (67.2 %)

67 (65.7 %)

0.0002

 Grades II–IV, n (%)

629 (25.6 %)

229 (32.8 %)

35 (34.3 %)

 

 Grades III–IV, n (%)

234 (9.5 %)

90 (12.9 %)

11 (10.8 %)

0.035

 Missing, n

75

21

3

 

Chronic GVHDa

    

 All grades

35.0 % [32.9–37.2]

35.1 % [31.2–39]

44.4 % [33.6–54.6]

0.138

 Extensive

17.1 % [15.4–18.9]

15.2 % [12.3–18.5]

26.1 % [16.8–36.4]

0.047

 Limited, n

369

109

14

 

 Extensive, n

324

80

21

 

 Missing, n

38

18

5

 
  1. GVHD graft-versus-host disease
  2. aTwo-year cumulative incidence